4SC AG (VSC):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:4SC AG (VSC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10002
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
4SC AG (4SC) is a biopharmaceutical company that discovers and develops small molecule drugs for the treatment of cancer and autoimmune diseases. The company’s product focuses on epigenetics, cancer stem cells and cancer immunotherapy. Its product pipeline comprises therapeutic programs at various stages of clinical development and early-stage research projects including Resminostat, 4SC-202 and 4SC-208. The company’s research programs are related to cancer stem cells, ion channel blockers and cytokine modulation. It develops and markets products through partnerships with pharmaceutical and biotech companies. The company operates through its subsidiary 4SC Discovery GmbH. 4SC is headquartered in Bayern, Germany.

4SC AG (VSC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
4SC AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
4SC AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
4SC AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
4SC AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
4SC AG, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
4SC Plans To Enters Into Co-Development Agreement For Resminostat 10
4SC Enters Into Co-Development Agreement With Crelux And Ribological 11
Licensing Agreements 12
Maruho Enters into Licensing Agreement with 4SC 12
Link Health Enters into Licensing Agreement with 4SC 13
Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 14
Equity Offering 15
4SC Raises USD46 Million in Rights Offering of Shares 15
4SC Raises USD32 Million in Rights Offering of Shares 16
Debt Offering 17
4SC Raises USD0.6 Million in Second Tranche of Private Placement of Notes 17
Asset Transactions 18
Immunic Acquires Immunology Portfolio from 4SC 18
Acquisition 19
BioNTech Small Molecules Acquires 4SC Discovery from 4SC 19
4SC AG – Key Competitors 20
4SC AG – Key Employees 21
4SC AG – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Mar 21, 2018: 4SC announces results for financial year 2017 23
Aug 10, 2017: 4SC provides Q2 and 6M 2017 update 24
Product News 25
07/31/2018: 4SC announce first patient enrolled in 2nd dose cohort of Phase Ib/II study SENSITIZE of domatinostat (4SC-202) + pembrolizumab in melanoma 25
07/03/2018: Positive safety review of 4SC’s Phase Ib/II SENSITIZE study of domatinostat (4SC-202) + pembrolizumab in melanoma 26
06/11/2017: First patient enrolled in Phase Ib/II study SENSITIZE of 4SC-202 in melanoma 27
04/11/2017: New mechanistic insights into 4SC-202’s epigenetic mode of action 28
Other Significant Developments 29
Oct 25, 2018: 4SC provides Q3 business update and outlook 29
Oct 26, 2017: 4SC provides Q3 and 9M 2017 update 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
4SC AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
4SC AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
4SC AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
4SC AG, Deals By Therapy Area, 2012 to YTD 2018 8
4SC AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
4SC Plans To Enters Into Co-Development Agreement For Resminostat 10
4SC Enters Into Co-Development Agreement With Crelux And Ribological 11
Maruho Enters into Licensing Agreement with 4SC 12
Link Health Enters into Licensing Agreement with 4SC 13
Menarini Enters into Licensing and Development Agreement with 4SC for Resminostat 14
4SC Raises USD46 Million in Rights Offering of Shares 15
4SC Raises USD32 Million in Rights Offering of Shares 16
4SC Raises USD0.6 Million in Second Tranche of Private Placement of Notes 17
Immunic Acquires Immunology Portfolio from 4SC 18
BioNTech Small Molecules Acquires 4SC Discovery from 4SC 19
4SC AG, Key Competitors 20
4SC AG, Key Employees 21

List of Figures
4SC AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
4SC AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
4SC AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
4SC AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
4SC AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
4SC AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
4SC AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[4SC AG (VSC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • PsychoGenics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary PsychoGenics Inc (PsychoGenics) is a preclinical contract research organization that offers treatment for CNS and orphan disorders.The company’s capabilities include electrophysiology, behavioral testing, translational EEG, molecular biology, quantitative histology and microdialysis. Its pro …
  • C&C Group plc:戦略・SWOT・企業財務分析
    C&C Group plc - Strategy, SWOT and Corporate Finance Report Summary C&C Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Dorel Industries Inc.:企業の戦略・SWOT・財務情報
    Dorel Industries Inc. - Strategy, SWOT and Corporate Finance Report Summary Dorel Industries Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Transport for London:企業の戦略的SWOT分析
    Transport for London - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Neogen Corp (NEOG):企業の財務・戦略的SWOT分析
    Neogen Corp (NEOG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • WorleyParsons Ltd (WOR):石油・ガス:M&Aディール及び事業提携情報
    Summary WorleyParsons Ltd (WorleyParsons) is a provider of professional services. Its services cover the full lifecycle, from creating new assets to sustaining and enhancing operating assets. The company provides integrated solution for deepwater developments with the associated subsea, pipelines, r …
  • Shionogi & Co Ltd (4507):企業の財務・戦略的SWOT分析
    Shionogi & Co Ltd (4507) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • S. Kumars Nationwide Limited:戦略・SWOT・企業財務分析
    S. Kumars Nationwide Limited - Strategy, SWOT and Corporate Finance Report Summary S. Kumars Nationwide Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Electricity Supply Board-エネルギー分野:企業M&A・提携分析
    Summary Electricity Supply Board (ESB) owned by Irish Government, is a diversified and vertically integrated utility that generates, transmits, and distributes and supplies electricity and gas. The company builds, owns and maintains transmission and distribution networks. It offers meter reading, an …
  • Nammo AS:企業の戦略・SWOT・財務情報
    Nammo AS - Strategy, SWOT and Corporate Finance Report Summary Nammo AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • CK Hutchison Holdings Ltd:企業のM&A・事業提携・投資動向
    CK Hutchison Holdings Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CK Hutchison Holdings Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • MRI Interventions Inc (MRIC):企業の財務・戦略的SWOT分析
    Summary MRI Interventions Inc (MRI Interventions) is a medical equipment company that develops and commercializes platforms for performing invasive surgical procedures. The company’s products include systems used for performing invasive surgeries on brain and heart. Its products are used for treatin …
  • Abreos Biosciences Inc-医療機器分野:企業M&A・提携分析
    Summary Abreos Biosciences Inc (Abreos Biosciences) is a biotechnology company that develops laboratory-based and point-of-care (POC) tests for precision dosing of biologic drugs. The company’s technology platform veritope, allow monitoring of monoclonal antibody drug levels in blood (novel or biosi …
  • Advantest Corporation (6857):企業の財務・戦略的SWOT分析
    Advantest Corporation (6857) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Grupo Financiero Galicia S.A. (GGAL3):企業の財務・戦略的SWOT分析
    Grupo Financiero Galicia S.A. (GGAL3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • State Grid Corporation of China:電力:M&Aディール及び事業提携情報
    Summary State Grid Corporation of China (SGCC) is an electric utility that builds and operates power grids, and distributes and transmits electricity. The utility offers energy efficient home appliances air conditioner, fan, TV set, washing machine, microwave oven, refrigerator, electric water heate …
  • Meritor, Inc. (MTOR):企業の財務・戦略的SWOT分析
    Meritor, Inc. (MTOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Lietuvos Energija UAB:電力:M&Aディール及び事業提携情報
    Summary Lietuvos Energija UAB (Lietuvos Energija) is a state-owned utility. The utility’s activities include power and heat distribution and supply; natural gas trade and distribution; construction and maintenance of power plants and grid; development of energy infrastructure and green energy; and d …
  • Meridian Energy Ltd (MEL):企業の財務・戦略的SWOT分析
    Meridian Energy Ltd (MEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Terna Energy SA (TENERGY):企業の財務・戦略的SWOT分析
    Terna Energy SA (TENERGY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆